Illumina, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
6.9
Neutral
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
ILMN
High-quality business with 34% return on equity and 19% profit margins.
⚠ analyst sentiment is cautious.
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
HOLD
Target $138.94 (+2.3%)
17 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
ILMN
MRK
24.7×
Trailing P/E
31.5×
23.0×
Forward P/E
11.5×
19.4%
Profit Margin
13.6%
68.4%
Gross Margin
76.6%
33.8%
ROE
—
4.8%
Revenue Growth
4.9%
6.1%
Earnings Growth
—
1.49
Beta
0.28
—
Price / Book
—
$20.6B
Market Cap
$277.0B
$74 – $156
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →